- Home
- CLDI vs BMRA Comparison
CLDI vs BMRA Comparison
Compare CLDI & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- BMRA
- Stock Information
- Founded
- CLDI 2014
- BMRA 1971
- Country
- CLDI United States
- BMRA United States
- Employees
- CLDI N/A
- BMRA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CLDI Health Care
- BMRA Health Care
- Exchange
- CLDI Nasdaq
- BMRA Nasdaq
- Market Cap
- CLDI 8.7M
- BMRA 7.9M
- IPO Year
- CLDI N/A
- BMRA N/A
- Fundamental
- Price
- CLDI $1.60
- BMRA $2.85
- Analyst Decision
- CLDI
- BMRA
- Analyst Count
- CLDI 0
- BMRA 0
- Target Price
- CLDI N/A
- BMRA N/A
- AVG Volume (30 Days)
- CLDI 141.6K
- BMRA 32.9K
- Earning Date
- CLDI 11-11-2025
- BMRA 10-10-2025
- Dividend Yield
- CLDI N/A
- BMRA N/A
- EPS Growth
- CLDI N/A
- BMRA N/A
- EPS
- CLDI N/A
- BMRA N/A
- Revenue
- CLDI N/A
- BMRA $5,311,000.00
- Revenue This Year
- CLDI N/A
- BMRA N/A
- Revenue Next Year
- CLDI N/A
- BMRA N/A
- P/E Ratio
- CLDI N/A
- BMRA N/A
- Revenue Growth
- CLDI N/A
- BMRA N/A
- 52 Week Low
- CLDI $1.41
- BMRA $2.08
- 52 Week High
- CLDI $46.68
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- CLDI 43.90
- BMRA 45.61
- Support Level
- CLDI $1.41
- BMRA $2.68
- Resistance Level
- CLDI $1.68
- BMRA $2.83
- Average True Range (ATR)
- CLDI 0.08
- BMRA 0.11
- MACD
- CLDI 0.05
- BMRA 0.01
- Stochastic Oscillator
- CLDI 66.74
- BMRA 54.84
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.